Everest Medicines is a Shanghai-based, Hong Kong-listed biopharmaceutical company with an integrated presence spanning research through commercial production. Its work is aimed at bringing innovative treatments to patients in China and other global markets, with a particular emphasis on addressing serious unmet medical needs. The company’s Jiashan manufacturing site began operating in 2022 and includes a 58,000-square-meter facility built to Chinese, U.S. and EU GMP standards.
GMP production quality management system compliant with Chinese, U.S. and EU standards
certification
Chinese pharmaceutical manufacturing license
registration